Botanova ads scrutinized
This article was originally published in The Tan Sheet
Executive SummaryThe U.K. Medicines and Healthcare products Regulatory Agency upholds three advertising complaints filed last fall against German pharmaceutical company Pascoe Pharmazeutische Praparate GmbH. The complaints allege marketing for Botanova (St. John's wort, passion flower and valerian) misleads consumers. The British Herbal Medicine Association and Schwabe Pharma complained Pascoe ads inappropriately touted Botanova has improved efficacy over other products. The claims violate U.K. ad requirements for traditional herbal medicines. BHMA also complained that Botanova press materials incorrectly said the product is not associated with drug-drug interactions. Pascoe revised the materials and confirmed future marketing material will comply with the U.K. requirements for advertising of registered traditional herbal medicines, according to notices MHRA posted July 17
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.